Insider Buying: Immuneering (NASDAQ:IMRX) Director Buys $87,000.00 in Stock

Immuneering Corporation (NASDAQ:IMRX) Director Peter Feinberg purchased 20,000 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were acquired at an average price of $4.35 per share, with a total value of $87,000.00. Following the transaction, the director owned 135,441 shares in the company, valued at approximately $589,168.35. The trade was a 17.32% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Immuneering Trading Down 1.3%

Shares of NASDAQ IMRX opened at $4.58 on Friday. The business has a 50-day moving average of $6.37 and a 200-day moving average of $5.78. The firm has a market capitalization of $295.73 million, a price-to-earnings ratio of -2.57 and a beta of 0.48. Immuneering Corporation has a 12 month low of $1.10 and a 12 month high of $10.08.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Wednesday, November 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). On average, analysts predict that Immuneering Corporation will post -1.86 earnings per share for the current year.

Institutional Trading of Immuneering

Several hedge funds and other institutional investors have recently bought and sold shares of IMRX. Sanofi bought a new stake in Immuneering in the 3rd quarter worth $18,960,000. Vanguard Group Inc. raised its stake in shares of Immuneering by 128.5% during the third quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock valued at $16,907,000 after acquiring an additional 1,358,322 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of Immuneering during the third quarter worth about $6,602,000. Blue Owl Capital Holdings LP purchased a new stake in shares of Immuneering during the third quarter worth about $3,850,000. Finally, Burkehill Global Management LP bought a new stake in shares of Immuneering in the third quarter worth about $2,100,000. Institutional investors own 67.65% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Mizuho set a $12.00 target price on shares of Immuneering in a research report on Wednesday, October 29th. Oppenheimer upped their price objective on Immuneering from $21.00 to $30.00 and gave the stock an “outperform” rating in a report on Thursday, September 25th. Leerink Partners began coverage on Immuneering in a research report on Friday, October 31st. They set an “outperform” rating and a $15.00 price objective on the stock. Wall Street Zen cut Immuneering from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Finally, HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Immuneering in a research report on Tuesday, September 30th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $16.50.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.